NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.88 -0.12 (-0.15%) GOLD FUTURES
2,316.50 +5.50 (+0.24%) DOW
38,224.72 +321.43 (+0.85%) Bitcoin GBP
47,283.61 +894.51 (+1.93%)
ASLAN Pharmaceuticals Limited (ASLN)
| Previous close | 0.4571 |
| Open | 0.4643 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.4350 - 0.4799 |
| 52-week range | 0.3920 - 4.6900 |
| Volume | |
| Avg. volume | 1,256,883 |
| Market cap | 10.352M |
| Beta (5Y monthly) | 1.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.7500 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.50 |
GlobeNewswireASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab.The findings will deepen understanding of the biology underlying the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumab.The first part of the collaboration will focus on receptor biology and kinetics to investigate the cellular and molecular basis of ebla
- GlobeNewswire
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
ASLAN management will present new data from the interim analysis of the TREK-DX studyRegister here to attend the webinar event on May 7, 2024 at 8:00 AM ET SAN MATEO, Calif. and SINGAPORE, April 30, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host a virtual Key Opinion Leader (KOL) Event, “Treatment Options for Atopic
- GlobeNewswire
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease has been accepted for a late breaking poster presentation at the American Thoracic Society International Conference 2024. The conference is taking place in San Diego, Califo
